

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Axitinib

February 10, 2026

### **Therapeutic category**

Other antitumor agents

### **Non-proprietary name**

Axitinib

### **Safety measure**

PRECAUTIONS should be revised.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
This English version is intended to be a reference material to provide convenience for users.  
In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (newly added)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Acute pancreatitis</u> <u>If symptoms such as abdominal pain or pancreatic enzyme increased are observed, appropriate measures including discontinuation of treatment with this drug should be taken.</u>